Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by amorakon Mar 30, 2007 11:47am
360 Views
Post# 12519441

Think carefully...

Think carefully...What I see a lot of right now on this forum is a number of people who are tuning their arguments and prognostications to the market's behaviour instead of thinking about the RVX story. The RVX story as it stands at this moment is immutable. No market behaviour can change it. And the philosophical stuff - great reading, a balm to the market weary, of little value. Laziness. Think about the facts - put them in order - draw the conclusions. As far as the parallel approach to selling RVX and moving towards Phase I, what would the Toronto analysts have RVX do, shut down its research until a buyer appears? That's lazy thinking in the extreme. To draw a negative conclusion from that is your business but act on it at your own peril. What we do with our RVX shares and the market while we wait for a buyout is our own choice. I've locked in a three-bagger overall and the rest rides. Anybody else in my position would and should do the same. But I have to make the decision every day about the rest of it. I'm holding it. RVX will be bought out. Pfizer set the price of $1.3 billion for a drug that couldn't reach market and one or two small molecule candidates. Despite Pfizer's recent cutbacks, the Esperion team is still working on it all. Pfizer set the price. Pfizer is keeping it alive. Apo-A1 is the way of the future and RVX has it.
Bullboard Posts